Thai Optical Group PCL

Thai Optical Group PCL maintains a debt-to-equity ratio of 0.55, indicating a moderate level of leverage relative to its equity base. The company's liquidity position is characterized by a current ratio of 1.76, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

In terms of profitability, the company reports a return on equity (ROE) of 4.76% and a return on assets (ROA) of 2.67%. These figures suggest that the company is generating returns, but at a relatively modest rate compared to industry benchmarks. The operating margin, calculated as operating income divided by revenue, is 15.76%, which is a key metric for evaluating operational efficiency in the medical equipment and supplies industry.

The company's revenue is primarily concentrated in its domestic market, with no disclosed international revenue segments. This concentration may expose the company to regional economic fluctuations and regulatory changes in Thailand. The lack of geographic diversification could limit growth opportunities and increase vulnerability to local market conditions.

Looking ahead, the company's growth trajectory is expected to be influenced by its capital expenditure and operating cash flow. The company's capital expenditure for the period was negative at -24.264 million THB, indicating a reduction in capital spending. The operating cash flow of 165.678 million THB suggests the company is generating positive cash from operations, which is a positive sign for its ability to fund future growth and meet obligations.

The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key risk flag of negative net cash after subtracting total debt highlights the need for careful liquidity management. The dilution risk is low, indicating that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders.

Recent events and filings have not disclosed any major strategic shifts or significant operational changes. The company's financial performance and risk profile remain stable, with no immediate signs of distress or aggressive expansion.

Operating and net margins exceed 75th percentile of medical equipment cohort peers, indicating superior profitability.

Free cash flow surged 132.3% year-over-year to THB 49 million, demonstrating strong cash generation recovery.

Return on equity of 4.8% outperforms the cohort median of 1.4%, showing efficient capital utilization.

Cash conversion ratio of 1.49 exceeds the cohort median of 0.84, highlighting effective working capital management.

Revenue grew 4.9% annually over four years, providing a stable top-line growth foundation despite recent volatility.

Debt-to-equity ratio of 0.55 ranks in the bottom quartile of peers, indicating elevated financial leverage risk.

High credit risk flag suggests potential challenges in debt servicing or counterparty reliability for the company.

Net income CAGR of -4.6% over four years indicates a long-term downward trend in earnings power.

Revenue THB 2.92B, +22,8% YoY; Operating income +28,1% YoY.

• ▍Revenue THB 2.92B, +22,8% YoY
• ▍Operating income +28,1% YoY
• ▍Net income +30,1% YoY
• ▍Free cash flow −10,2% YoY
• ▍Net margin 13.8%